ES2101865T3 - Igf-1 para mejorar el estado neural. - Google Patents
Igf-1 para mejorar el estado neural.Info
- Publication number
- ES2101865T3 ES2101865T3 ES92917908T ES92917908T ES2101865T3 ES 2101865 T3 ES2101865 T3 ES 2101865T3 ES 92917908 T ES92917908 T ES 92917908T ES 92917908 T ES92917908 T ES 92917908T ES 2101865 T3 ES2101865 T3 ES 2101865T3
- Authority
- ES
- Spain
- Prior art keywords
- nervous system
- central nervous
- igf
- improve
- analogues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Color Image Communication Systems (AREA)
Abstract
SE PRESENTA UN METODO PARA TRATAR LAS LESIONES O ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL QUE PREDOMINANTEMENTE AFECTAN LAS CELULAS NEURONALES GLIA Y/O NO COLINERGICAS QUE SE CARACTERIZA EN QUE COMPRENDE EL PASO DE INCREMENTAR LAS CONCENTRACIONES ACTIVAS DEL FACTOR DE CRECIMIENTO I SIMILAR A LA INSULINA Y/O ANALOGOS DEL MISMO EN EL SISTEMA NERVIOSO CENTRAL DEL PACIENTE. LA INVENCION TAMBIEN SUMINISTRA COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN EL FACTOR DE CRECIMIENTO I SIMILAR A LA INSULINA Y/O ANALOGOS DEL MISMO PARA SU ADMINISTRACION A UN PACIENTE DESPUES DE LOS DAÑOS NEURONALES, DICHAS COMPOSICIONES SON UTILES PARA MINIMIZAR LOS DAÑOS EN EL SISTEMA NERVIOS CENTRAL QUE DE OTRA FORMA SE PRODUCIRIAN SIGUIENDO A LA LESION.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ23921191 | 1991-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2101865T3 true ES2101865T3 (es) | 1997-07-16 |
Family
ID=19923685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES92917908T Expired - Lifetime ES2101865T3 (es) | 1991-08-01 | 1992-08-03 | Igf-1 para mejorar el estado neural. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US5714460A (es) |
| EP (1) | EP0597033B1 (es) |
| AT (1) | ATE151293T1 (es) |
| CA (1) | CA2114251C (es) |
| DE (1) | DE69218948T2 (es) |
| DK (1) | DK0597033T3 (es) |
| ES (1) | ES2101865T3 (es) |
| GR (1) | GR3023874T3 (es) |
| WO (1) | WO1993002695A1 (es) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6440928B1 (en) | 1988-12-06 | 2002-08-27 | Colorado State University Research Foundation | Method for treating diabetic neuropathy with NGF |
| US6723699B1 (en) * | 1989-06-05 | 2004-04-20 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
| US6693076B1 (en) * | 1989-06-05 | 2004-02-17 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
| US6310040B1 (en) * | 1991-11-08 | 2001-10-30 | Cephalon, Inc. | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs |
| US5420112A (en) * | 1992-06-12 | 1995-05-30 | Lewis; Michael E. | Prevention and treatment of peripheral neuropathy |
| EP0659083B1 (en) * | 1992-06-12 | 1999-12-22 | Cephalon, Inc. | Prevention and treatment of peripheral neuropathy |
| US20070078089A1 (en) * | 1992-07-06 | 2007-04-05 | Ishii Douglas N | Method for effecting changes in the central nervous system by administration of IGF-I or IGF-II |
| SE9301667D0 (sv) * | 1993-05-14 | 1993-05-14 | Kabi Pharmacia Ab | New use |
| AU693489B2 (en) * | 1993-11-15 | 1998-07-02 | Celtrix Pharmaceuticals, Inc. | Method of treating neurological disorders |
| CA2178711A1 (en) | 1993-12-23 | 1995-06-29 | Peter David Gluckman | Composition and methods to improve neural outcome |
| US6812208B2 (en) | 1993-12-23 | 2004-11-02 | Neuronz Ltd. | Methods to improve neural outcome |
| US5656605A (en) * | 1994-01-26 | 1997-08-12 | Institute Of Molecular Biology, Inc. | Device to promote drug-induced nerve regeneration |
| SE9402332D0 (sv) * | 1994-07-01 | 1994-07-01 | Pharmacia Ab | Igf-1 |
| US5712249A (en) * | 1994-09-08 | 1998-01-27 | Ciba-Geigy Corporation | Use of insulin-like growth factors I and II for inhibition of inflammatory response |
| US5965531A (en) * | 1995-08-31 | 1999-10-12 | National Institutes Of Health | Method of reducing perivascular lesions using insulin-like growth factor I |
| EP0874641B1 (en) * | 1995-12-13 | 2003-04-09 | Aurogen Incorporated | Igf-i and -ii for the treatment of diseases of the central nervous system |
| US6015786A (en) * | 1997-02-25 | 2000-01-18 | Celtrix Pharmaceuticals, Inc. | Method for increasing sex steroid levels using IGF or IGF/IGFBP-3 |
| US6514937B1 (en) | 1997-02-25 | 2003-02-04 | Celtrix Pharmaceuticals, Inc. | Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3 |
| US6025368A (en) * | 1997-02-25 | 2000-02-15 | Celtrix Pharmaceuticals, Inc. | Method for treating the symptoms of chronic stress-related disorders using IGF |
| US6420518B1 (en) | 1997-04-04 | 2002-07-16 | Genetech, Inc. | Insulin-like growth factor agonist molecules |
| US6121416A (en) * | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
| US6187906B1 (en) * | 1997-08-11 | 2001-02-13 | Aukland Uniservices Limited | Methods to improve neural outcome |
| WO1999020299A1 (en) * | 1997-10-17 | 1999-04-29 | Spencer E Martin | Human urinary incontinence and methods of treatment |
| US6627746B1 (en) | 1998-04-17 | 2003-09-30 | Exelixis, Inc. | Nucleic acids and proteins of C. elegans insulin-like genes and uses thereof |
| CN1305383A (zh) * | 1998-06-15 | 2001-07-25 | 诺兰兹公司 | 酪氨酸羟化酶的调节 |
| AU762351B2 (en) * | 1999-01-06 | 2003-06-26 | Genentech Inc. | Insulin-like growth factor (IGF) I mutant variants |
| ES2329220T3 (es) * | 1999-01-06 | 2009-11-24 | Genentech, Inc. | Variantes mutantes del factor de crecimiento similar a insulina (igf) i. |
| AU4503801A (en) * | 1999-10-27 | 2001-06-04 | Chiron Corporation | Temperature dependent neuronal rescue |
| AU2001263215A1 (en) | 2000-05-16 | 2001-11-26 | Genentech Inc. | Method for treating cartilage disorders |
| ATE463252T1 (de) * | 2000-08-29 | 2010-04-15 | Aurogen Inc | Methode zur behandlung des zentralnervensystems durch applikation von strukturanaloga von igf |
| US20030027755A1 (en) * | 2000-12-08 | 2003-02-06 | Jian Guan | Compositions and methods for the rescue of white matter |
| DE60217066T4 (de) * | 2001-02-09 | 2010-07-01 | Genentech, Inc., South San Francisco | Kristallisierung von igf-1 |
| US6682753B2 (en) * | 2001-03-23 | 2004-01-27 | Neuronz Limited | Methods for promoting weight gain using GPE-related compounds |
| US7605177B2 (en) | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
| US20070004641A1 (en) * | 2001-05-24 | 2007-01-04 | Neuren Pharmaceuticals Limited | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate |
| US7714020B2 (en) | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
| EP1401808B1 (en) | 2001-05-24 | 2009-07-08 | Neuren Pharmaceuticals Limited | Gpe analogs and peptidomimetics |
| US6914049B2 (en) | 2001-09-18 | 2005-07-05 | Bioexpertise, Llc | IGF-binding protein-derived peptide or small molecule |
| EP1435986B1 (en) * | 2001-09-18 | 2008-01-02 | Bioexpertise, Llc | Igf-binding protein-derived peptide |
| US7232798B2 (en) * | 2001-11-13 | 2007-06-19 | Tran Loi H | Neuroprotection and neuroegenisis by administering cyclic prolyl glycine |
| GB0202906D0 (en) * | 2002-02-07 | 2002-03-27 | Univ London | Prevention of myocardial damage |
| DK2274978T3 (en) | 2003-09-12 | 2015-06-15 | Ipsen Biopharmaceuticals Inc | Methods of treating an insulin-like growth factor-I (IGF-I) deficiency |
| AU2004278311A1 (en) * | 2003-10-03 | 2005-04-14 | Genentech, Inc. | IGF binding proteins |
| US7220729B2 (en) * | 2004-05-10 | 2007-05-22 | Academia Sinica | Huntington's Disease Treatment |
| EP1674113A1 (en) * | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
| WO2006097682A1 (en) * | 2005-03-18 | 2006-09-21 | Ucl Business Plc | Mechano growth factor peptides and their use |
| US8969295B2 (en) * | 2006-04-14 | 2015-03-03 | Massachusetts Institute Of Technology | Identifying and modulating molecular pathways that mediate nervous system plasticity |
| BRPI0715754A2 (pt) | 2006-08-31 | 2013-07-09 | Hoffmann La Roche | mÉtodo para a produÇço de fator do crescimento similar Á insulina i |
| CL2007002502A1 (es) | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
| BRPI0812768A2 (pt) * | 2007-06-08 | 2014-12-02 | Massachusetts Inst Technology | Igf para o tratamento de síndrome de rett e transtornos sinápticos. |
| WO2009121759A2 (en) * | 2008-04-03 | 2009-10-08 | F. Hoffmann-La Roche Ag | Use of pegylated igf-i variants for the treatment of neuromuscular disorders |
| US20110045510A1 (en) * | 2008-04-03 | 2011-02-24 | Kurt Lang | Pegylated insulin-like-growth-factor assay |
| US20110152188A1 (en) | 2009-12-23 | 2011-06-23 | Hanns-Christian Mahler | Pharmaceutical compositions of igf/i proteins |
| US20180200301A1 (en) * | 2015-05-21 | 2018-07-19 | Shanghai Institutes For Biological Sciences Chinese Academy Of Sciences | Low-Oxygen-Treated Mesenchymal Stem Cell and Use Thereof |
| KR102245539B1 (ko) | 2018-02-12 | 2021-04-29 | 주식회사 지앤피바이오사이언스 | 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물 |
| MA53500A (fr) | 2018-05-15 | 2021-08-18 | Lloyd Hung Loi Tran | Composition d'agent thérapeutique et procédé d'utilisation, pour le traitement d'un trouble cognitif léger, de la dépression et de troubles psychologiques |
| US20210008172A1 (en) | 2019-07-11 | 2021-01-14 | Opko Biologics Ltd. | Long-acting igf-1 or igf-1 variants and methods of producing same |
| JP2022547948A (ja) | 2019-09-09 | 2022-11-16 | ザ・ユニバーシティ・オブ・シカゴ | 片頭痛の処置のための併用療法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8703625D0 (sv) * | 1987-09-18 | 1987-09-18 | Kabivitrum Ab | New medical use |
| US5817623A (en) | 1995-03-06 | 1998-10-06 | Univ Colorado State Res Found | Method for treating diabetic peripheral neuropathy with IGF-I or IGF-II |
| US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
| EP0484416A1 (en) * | 1989-07-27 | 1992-05-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Regulation of nerve growth factor synthesis in the central nervous system |
| US5219837A (en) * | 1990-06-21 | 1993-06-15 | Trustees Of The University Of Pennsylvania | Method of stimulating myelination of cells |
| US5861373A (en) * | 1991-08-01 | 1999-01-19 | Genentech, Inc | IGF-1 to improve the neural condition |
| US20070078089A1 (en) | 1992-07-06 | 2007-04-05 | Ishii Douglas N | Method for effecting changes in the central nervous system by administration of IGF-I or IGF-II |
-
1992
- 1992-08-03 ES ES92917908T patent/ES2101865T3/es not_active Expired - Lifetime
- 1992-08-03 AT AT92917908T patent/ATE151293T1/de not_active IP Right Cessation
- 1992-08-03 WO PCT/US1992/006389 patent/WO1993002695A1/en not_active Ceased
- 1992-08-03 DK DK92917908.3T patent/DK0597033T3/da active
- 1992-08-03 CA CA002114251A patent/CA2114251C/en not_active Expired - Lifetime
- 1992-08-03 DE DE69218948T patent/DE69218948T2/de not_active Revoked
- 1992-08-03 EP EP92917908A patent/EP0597033B1/en not_active Revoked
-
1995
- 1995-06-02 US US08/460,365 patent/US5714460A/en not_active Ceased
-
1997
- 1997-06-24 GR GR970401517T patent/GR3023874T3/el unknown
-
2003
- 2003-06-27 US US10/606,745 patent/USRE43982E1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2114251C (en) | 2007-11-06 |
| GR3023874T3 (en) | 1997-09-30 |
| DE69218948D1 (de) | 1997-05-15 |
| WO1993002695A1 (en) | 1993-02-18 |
| DE69218948T2 (de) | 1997-07-31 |
| DK0597033T3 (da) | 1997-06-02 |
| EP0597033A1 (en) | 1994-05-18 |
| US5714460A (en) | 1998-02-03 |
| CA2114251A1 (en) | 1993-02-18 |
| EP0597033B1 (en) | 1997-04-09 |
| USRE43982E1 (en) | 2013-02-05 |
| ATE151293T1 (de) | 1997-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GR3023874T3 (en) | Igf-1 to improve the neural condition. | |
| CA2122058A1 (en) | Tgf-beta to improve neural outcome | |
| DE68911068T2 (de) | EGF zur Vorbeugung von Gewebeschädigung nach Ischemie. | |
| GB9316895D0 (en) | Hepatoselective insulin analogues | |
| ES2162615T3 (es) | Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina. | |
| HUT51136A (en) | Process for producing pharmaceutical compositions for treating schisophreny, containing l-deprenil as active component | |
| ATE515265T1 (de) | Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen | |
| MY131805A (en) | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis. | |
| NO990088D0 (no) | Farmas÷ytiske preparater omfattende S-(-)-N-propargyl-1-aminoindamin | |
| NZ248377A (en) | Use of interleukin-1 beta protease and interleukin-1 beta protease inhibitors | |
| DE69533112T2 (de) | Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken | |
| DE69230112D1 (de) | Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin | |
| AU6586896A (en) | Fatty acid treatment | |
| WO1994008551A3 (en) | Pharmaceutical compositions and methods for treating cold symptoms | |
| EP0798000A3 (en) | Treating disorders by application of insulin-like growth factors and analogs | |
| ZA911496B (en) | Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders | |
| ATE112684T1 (de) | Verwendung von igf-ii zur behandlung von knochenkrankheiten. | |
| PT97785A (pt) | Metodo para a tratamento da impotencia utilizando, por exemplo, doxazosina | |
| BR9708287A (pt) | Processo para tratar ou prevenir um distúrbio do sistema nervoso central em um ser humano, para eliciar um efeito antiemético em um ser humano e para tratar um estado de doença em um ser humano, composição farmacêutica para tratar de distúrbios do sistema nervoso central em um ser humano, e, forma de dosagem unitária farmacêutica | |
| BR9500436A (pt) | Produtos uso de um g-csf uso de uma proteína tnf ligante processo para o tratamento e/ou prevenção do choque séptico | |
| RU94041207A (ru) | Средство для лечения заболеваний, поражающих нервную систему | |
| PT817646E (pt) | Metodos de tratamento da inflamacao e formulacoes para esse fim | |
| CA2108330A1 (en) | Enhancer for the Antianemia Effect of Erythropoietin and Method of Augmenting the Antianemia Effect of Erythropoietin | |
| EP0744176A3 (en) | Methods for inhibiting bone loss | |
| CO5031290A1 (es) | Formulacion lo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 597033 Country of ref document: ES |